Regado Biosciences to Present at the Needham & Company’s 10th Annual Healthcare Conference in New York City

BASKING RIDGE, N.J., March 30, 2011 /PRNewswire/ — Regado
Biosciences, a privately held company pioneering the development of
antithrombotic aptamers with active control agents, announced that
David J. Mazzo, PhD, President and CEO, will be presenting at the
Needham & Company’s 10th Annual Healthcare Conference at the
New York Palace Hotel in New York City on Wednesday, April 6, 2011
at 11:20 a.m. EDT.  The presentation will include an overview
of the Company’s pipeline with emphasis on the lead development
program, the innovative anticoagulant system REG1, including a
summary of the REG1 phase 2b trial (RADAR) results.

ABOUT REGADO BIOSCIENCES

Regado Biosciences, Inc. is a private biopharmaceutical company
pioneering a new therapeutic technology with the creation and
development of proprietary controllable aptamer drug systems.
 Each system comprises a nuclease-stabilized RNA aptamer, the
therapeutic effect of which can be reversed partially or completely
in real time by its specific and complementary oligonucleotide
active control agent.  This technology is being applied to
injectable antithrombotics (including anticoagulants and
antiplatelet agents) in the acute and sub-acute care cardiovascular
setting, a multi-billion dollar world-wide market in need of drugs
with improved safety profiles and a greater degree of therapeutic
control.  The products in Regado’s pipeline are designed to
act as optimized antithrombotics, uniquely concomitantly minimizing
the risk of ischemia and bleeding, and, by allowing patient
specific tuning of the desired therapeutic effect, providing a safe
and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  

Regado’s lead program, the anticoagulant system REG1, consists
of two parenteral agents both administered by IV bolus, the first
being a potent highly selective Factor IXa inhibitor (pegnivacogin,
a.k.a. RB006) and the second being its compleme

‘/>”/>

SOURCE